



Breast Cancer Radiotherapy: The State of the Art

Guest Editor:

Dr. Youlia Kirova

Associate Professor of Radiation
Oncology UVSQ, Department of
Radiation Oncology, Institut
Curie, 75005 Paris, France

Deadline for manuscript
submissions:

closed (31 January 2022)

Message from the Guest Editor

Dear Colleagues,

Adjuvant breast radiotherapy improves local control and reduces cancer-specific mortality; however first-generation techniques were associated with an increased risk of long term toxicity, a direct consequence of the wide irradiation fields which were used at that time and which exposed substantial cardiac volumes. Breast radiotherapy has fortunately evolved; currently, cardiac sparing can be efficiently achieved thanks to state-of-the-art techniques such as rotational intensity modulated radiation therapy (IMRT) or protontherapy. New molecules are arriving in the breast cancer treatment and it is important to know the efficacy and toxicity of these associations. This Special Issue is trying to respond of some of this questions.

Prof. Youlia Kirova
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)